|Tatsutoshi Nakahata M.D., Ph.D.
[ Contact ]
Our laboratory is studying the establishment of iPS cells from patients with various diseases. Our target diseases include Duchenne's muscular dystrophy, amyotrophic lateral sclerosis, Parkinson's disease, type I diabetes, congenital immunodeficiency, metabolic storage disease, and Fanconi's syndrome. Patient-derived iPS cells are useful for elucidation of the pathologies of established hereditary diseases. Disease-specific iPS cells from patients with unknown hereditary dispositions may be a key to understand intercellular interactions and environmental factors influencing pathogenesis of various diseases. These cells are also useful for verification of the safety of drugs and in the search for new therapeutic agents. If their safety is ensured, patient-derived iPS cells may facilitate cell transplantation therapy in combination with gene therapy for individual patients.